Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 21:31:42时区推断·⟳ 抓取 21:32:48·⚡ 决策 07-28 21:33:58 +1m10s·90.9 天前
强生股价创历史新高的行情回顾缺乏新增交易催化
本文主要是 Investing.com 对强生股价创历史新高、近期财报和评级变化的回顾，没有披露新的订单、审批、指引上修或公司级突发事实。
📄 原文Investing.com↗ 原文
Johnson and Johnson stock reaches all-time high at 270.0 USD
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation Johnson and Johnson stock has reached an all-…
不做 强生（JNJ.US）
股价创历史新高和近期财报/评级/收购回顾不是新增公司级催化，且超大市值主标的缺乏相对市值可量化增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本文主要是 Investing.com 对强生股价创历史新高、近期财报和评级变化的回顾，没有披露新的订单、审批、指引上修或公司级突发事实。
- 强生已是约6409亿美元市值的超大盘医药股，单纯股价创新高和付费研究推广不构成短周期可量化增量。
主要风险
- 若后续出现新的正式指引上修、重大药品审批或并购条款，需按新事件重新研判。
原文全文
展开原文 · 2,455 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
Johnson and Johnson stock has reached an all-time high, hitting a price of 270.0 USD, just above its 52-week high of $269.43. The healthcare giant now commands a market capitalization of $640.91 billion. This milestone reflects a significant growth trajectory, as the company’s stock has experienced a remarkable 58.2% increase over the past year—data from InvestingPro shows an even stronger 64% total return. According to InvestingPro Tips, JNJ has raised its dividend for 55 consecutive years, underscoring its financial stability with a current yield of 2.02%. The robust performance underscores investor confidence in Johnson and Johnson’s market strategies and financial health, as it continues to navigate the competitive landscape of the healthcare industry. While InvestingPro analysis suggests the stock is slightly overvalued at current levels, the company maintains a "GREAT" financial health score. Investors seeking deeper insights can access 12 additional ProTips and comprehensive analysis through JNJ’s Pro Research Report.
In other recent news, Johnson & Johnson reported a robust second-quarter performance, with adjusted earnings per share reaching $2.90 on revenue of $25.31 billion. These figures surpassed Wall Street expectations, which had projected $2.86 per share and $25.02 billion in revenue. The company also increased its full-year outlook, driven by strong demand in its Innovative Medicine division and steady growth in MedTech. In light of these results, Freedom Capital upgraded Johnson & Johnson’s stock rating from Hold to Buy, raising its price target to $280, citing stronger-than-expected revenue from products like TREMFYA, CAPLYTA, and SPRAVATO. Additionally, Bernstein SocGen Group adjusted its price target for the company to $261, maintaining a Market Perform rating after the earnings beat. Guggenheim reiterated its Buy rating with a price target of $270, noting that the company’s sales were slightly below its estimate but still exceeded consensus expectations. In other developments, DePuy Synthes, a subsidiary of Johnson & Johnson, acquired Expanding Innovations, a company specializing in expandable implant technology for spine surgery. This acquisition aims to enhance DePuy Synthes’ offerings in spinal procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Johnson and Johnson stock has reached an all-time high, hitting a price of 270.0 USD, just above its 52-week high of $269.43. The healthcare giant now commands a market capitalization of $640.91 billion. This milestone reflects a significant growth trajectory, as the company’s stock has experienced a remarkable 58.2% increase over the past year—data from InvestingPro shows an even stronger 64% total return. According to InvestingPro Tips, JNJ has raised its dividend for 55 consecutive years, underscoring its financial stability with a current yield of 2.02%. The robust performance underscores investor confidence in Johnson and Johnson’s market strategies and financial health, as it continues to navigate the competitive landscape of the healthcare industry. While InvestingPro analysis suggests the stock is slightly overvalued at current levels, the company maintains a "GREAT" financial health score. Investors seeking deeper insights can access 12 additional ProTips and comprehensive analysis through JNJ’s Pro Research Report.
In other recent news, Johnson & Johnson reported a robust second-quarter performance, with adjusted earnings per share reaching $2.90 on revenue of $25.31 billion. These figures surpassed Wall Street expectations, which had projected $2.86 per share and $25.02 billion in revenue. The company also increased its full-year outlook, driven by strong demand in its Innovative Medicine division and steady growth in MedTech. In light of these results, Freedom Capital upgraded Johnson & Johnson’s stock rating from Hold to Buy, raising its price target to $280, citing stronger-than-expected revenue from products like TREMFYA, CAPLYTA, and SPRAVATO. Additionally, Bernstein SocGen Group adjusted its price target for the company to $261, maintaining a Market Perform rating after the earnings beat. Guggenheim reiterated its Buy rating with a price target of $270, noting that the company’s sales were slightly below its estimate but still exceeded consensus expectations. In other developments, DePuy Synthes, a subsidiary of Johnson & Johnson, acquired Expanding Innovations, a company specializing in expandable implant technology for spine surgery. This acquisition aims to enhance DePuy Synthes’ offerings in spinal procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。